RxDoctor Payments Data

Lori Trefts, MD

Neurology · Brunswick, GANPI 1306875117

Payments from drug & device makers

$16,380in general payments, 2019–2025

Across 718 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$1K
  • Banner Life Sciences, LLC$912
  • UCB, Inc.$780
  • AstraZeneca$695
  • Novartis$663
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$7505%
  • Speaking & faculty fees$9556%
  • Food & beverage$14,65689%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)84$1,496
Biogen36$1,354
Banner Life Sciences, LLC2$912
UCB, Inc.36$780
AstraZeneca(2 entities)29$695
Novartis36$663
EMD Serono, Inc.30$658
Genentech USA, Inc.32$650
Eisai Inc.25$603
Lundbeck LLC29$577
Pfizer31$516
Argenx US, Inc.18$422
CSL Behring17$403
Adamas Pharmaceuticals, Inc.24$388
Amgen(2 entities)21$382
ANI Pharmaceuticals, Inc.5$368
Bristol Myers Squibb7$359
SK Life Science, Inc.15$355
MDD US Operations, LLC8$309
Lilly USA, LLC17$299
TG Therapeutics, Inc.11$275
Kyowa Kirin, Inc.14$257
Teva Pharmaceuticals USA, Inc.14$233
Avanir Pharmaceuticals, Inc.13$214
Grifols USA, LLC11$196
Acadia Pharmaceuticals Inc12$194
Mallinckrodt Hospital Products Inc.10$192
Neurelis, Inc.9$171
Tanabe Pharma America, Inc.9$165
Sanofi9$163
Neurocrine Biosciences, Inc.8$157
Otsuka America Pharmaceutical, Inc.9$153
Biohaven Pharmaceutical Holding Company Ltd.7$142
Johnson & Johnson(2 entities)7$125
Sumitomo Pharma America, Inc.7$125
Boston Scientific1$102
Amneal Pharmaceuticals LLC4$101
Catalyst Pharmaceuticals, Inc.4$97
Biohaven Pharmaceuticals, Inc.5$93
GE HealthCare3$91
Jazz Pharmaceuticals Inc.4$86
Supernus Pharmaceuticals, Inc.5$80
Impel Pharmaceuticals Inc.4$77
Sunovion Pharmaceuticals Inc.5$71
Abbott2$60
Mallinckrodt Enterprises LLC2$56
Acorda Therapeutics, Inc3$55
Upsher-smith Laboratories LLC2$48
Merz Pharmaceuticals, LLC1$46
Amylyx Pharmaceuticals, Inc.2$46
Arbor Pharmaceuticals, Inc.3$45
Vanda Pharmaceuticals Inc.2$43
Immedica Pharma US, Inc.2$35
Medtronic2$34
Alnylam Pharmaceuticals Inc.2$28
Averitas Pharma Inc.1$24
Azurity Pharmaceuticals, Inc.1$22
E.r. Squibb & Sons, L.L.C.1$20
Avion Pharmaceuticals1$15
Zyla Life Sciences, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,380 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$129,905
Medicare patients
361
Services billed
5,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlatopaGlatiramer Acetate46$123,648
Emgality PenGalcanezumab-Gnlm54$58,570
UbrelvyUbrogepant32$44,756
Nurtec OdtRimegepant Sulfate33$33,822
RytaryCarbidopa/Levodopa21$26,953
QuliptaAtogepant15$20,718
Topiramate ErTopiramate16$19,829
Emgality SyringeGalcanezumab-Gnlm19$19,611
Glatiramer Acetate11$15,251
Levetiracetam201$5,458
Lacosamide29$4,021
Levetiracetam ErLevetiracetam34$3,690
Memantine Hcl163$3,651
Carbidopa-LevodopaCarbidopa/Levodopa60$2,768
Gabapentin101$2,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,496$65,47447 claims
PfizerNurtec Odt$516$33,82233 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$101$27,85333 claims
Upsher-smith Laboratories LLCTopiramate$48$92087 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 506 neurology providers in Georgia.

Other neurology in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →